Related Experiment Video
Updated: Mar 22, 2026

Author Spotlight: In Vivo Assessment of Thyroid Hormone Disruption Using the THAI Mouse Model
Published on: October 6, 2023
Update of OECD DART guidelines with endocrine disruptor relevant endpoints: Practical considerations
Manon Beekhuijzen1, Francois van Otterdijk1, Willemien Wieland1
1WIL Research Europe B.V., 's-Hertogenbosch, The Netherlands.
Abstract:
In 1998, the OECD initiated a high-priority project aimed at revising existing test guidelines and developing new test guidelines for screening of potential endocrine disruptors. In 2011, OECD 443 was adopted, and in 2015 OECD 421 and OECD 422 were updated with endocrine disruptor relevant endpoints. A feasibility study for the enhancement of OECD 414 with endocrine disruptor relevant endpoints is currently ongoing. The addition of these endpoints is considered crucial for gaining more information on endocrine disruptor potency of tested chemicals, however it should be noted that these additions have a major impact on the study designs and give rise to several practical challenges. The aim of this review is to discuss important aspects of these challenging study designs and to share our knowledge on their implementation in our laboratory. Together, this review can be used as guidance for other laboratories, study monitors and registration officers.
Related Concept Videos
Toxicity Testing in Animals
Teratogenicity
Clinically Relevant Drug Product Specifications: Methods of Establishment
Mutagenicity and Carcinogenicity
Therapeutic Drug Monitoring: Drug Analysis Methods
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

